Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 76

1.

Functional genomics to explore cancer cell vulnerabilities.

Kahle KT, Kozono D, Ng K, Hsieh G, Zinn PO, Nitta M, Chen CC.

Neurosurg Focus. 2010 Jan;28(1):E5. doi: 10.3171/2009.10.FOCUS09212.

PMID:
20043720
2.

Dissecting cancer pathways and vulnerabilities with RNAi.

Westbrook TF, Stegmeier F, Elledge SJ.

Cold Spring Harb Symp Quant Biol. 2005;70:435-44. Review.

PMID:
16869781
3.

Functional genomics and cancer drug target discovery.

Moody SE, Boehm JS, Barbie DA, Hahn WC.

Curr Opin Mol Ther. 2010 Jun;12(3):284-93. Review.

PMID:
20521217
4.

Integrated genomic and pharmacological approaches to identify synthetic lethal genes as cancer therapeutic targets.

Mizuarai S, Irie H, Schmatz DM, Kotani H.

Curr Mol Med. 2008 Dec;8(8):774-83. Review.

PMID:
19075675
5.

RNAi screening for the discovery of novel modulators of human disease.

Seyhan AA, Rya TE.

Curr Pharm Biotechnol. 2010 Nov;11(7):735-56. Review.

PMID:
20420566
6.

[RNA interference (RNAi) and its therapeutic potential in cancer].

Vázquez-Vega S, Contreras-Paredes A, Lizano-Soberón M, Amador-Molina A, García-Carrancá A, Sánchez-Suárez LP, Benítez-Bribiesca L.

Rev Invest Clin. 2010 Jan-Feb;62(1):81-90. Review. Spanish.

PMID:
20415062
7.

Genome-wide screening for gene function using RNAi in mammalian cells.

Cullen LM, Arndt GM.

Immunol Cell Biol. 2005 Jun;83(3):217-23. Review.

PMID:
15877598
8.

Genome-wide approaches for cancer gene discovery.

Lizardi PM, Forloni M, Wajapeyee N.

Trends Biotechnol. 2011 Nov;29(11):558-68. doi: 10.1016/j.tibtech.2011.06.003. Epub 2011 Jul 13. Review.

9.

RNAi and HTS: exploring cancer by systematic loss-of-function.

Willingham AT, Deveraux QL, Hampton GM, Aza-Blanc P.

Oncogene. 2004 Nov 1;23(51):8392-400. Review.

PMID:
15517021
10.

Understanding genomic alterations in cancer genomes using an integrative network approach.

Wang E.

Cancer Lett. 2013 Nov 1;340(2):261-9. doi: 10.1016/j.canlet.2012.11.050. Epub 2012 Dec 22. Review.

PMID:
23266571
11.

[Gene polymorphisms].

Robert J.

Bull Cancer. 2010 Nov;97(11):1253-64. doi: 10.1684/bdc.2010.1203. Review. French.

12.

Epigenetic mechanisms in glioblastoma multiforme.

Nagarajan RP, Costello JF.

Semin Cancer Biol. 2009 Jun;19(3):188-97. doi: 10.1016/j.semcancer.2009.02.005. Epub 2009 Feb 20. Review.

PMID:
19429483
13.

RNAi for functional genomics in plants.

McGinnis KM.

Brief Funct Genomics. 2010 Mar;9(2):111-7. doi: 10.1093/bfgp/elp052. Epub 2010 Jan 6. Review.

PMID:
20053816
14.

Functional Genomics in Pharmaceutical Drug Discovery.

Adams R, Steckel M, Nicke B.

Handb Exp Pharmacol. 2016;232:25-41. doi: 10.1007/164_2015_27. Review.

PMID:
26330261
15.

Functional genomic approaches targeting the wnt signaling network.

Dasgupta R.

Curr Drug Targets. 2009 Jul;10(7):620-31. Review.

PMID:
19601766
16.

Oncology studies using siRNA libraries: the dawn of RNAi-based genomics.

Sachse C, Echeverri CJ.

Oncogene. 2004 Nov 1;23(51):8384-91. Review.

PMID:
15517020
17.

Using RNAi to catch Drosophila genes in a web of interactions: insights into cancer research.

Dasgupta R, Perrimon N.

Oncogene. 2004 Nov 1;23(51):8359-65. Review.

PMID:
15517017
18.

[Application of RNAi library to oncology investigation].

Weng DH, Wang SX, Ma D.

Ai Zheng. 2008 Nov;27(11):1229-32. Review. Chinese.

PMID:
19000460
19.

Epidermal growth factor receptor as a therapeutic target in glioblastoma.

Kalman B, Szep E, Garzuly F, Post DE.

Neuromolecular Med. 2013 Jun;15(2):420-34. doi: 10.1007/s12017-013-8229-y. Epub 2013 Apr 11. Review.

PMID:
23575987
20.

RNAi screening for therapeutic targets in human malignancies.

Micklem DR, Lorens JB.

Curr Pharm Biotechnol. 2007 Dec;8(6):337-43. Review.

PMID:
18289042

Supplemental Content

Support Center